Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Inclacumab was generally well tolerated in THRIVE-131
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
